RT Journal Article
ID 12667f0538d1e135
A1 Vatovec, Christine
A1 Erten, Mujde Z. 
A1 Kolodinsky, Jane 
A1 Brown, Phil 
A1 Wood, Marie 
A1 James , Ted 
A1 Sprague, Brian L. 
T1 Ductal Carcinoma <i>In Situ</i>: A Brief Review of Treatment Variation and Impacts on Patients and Society
JF Critical Reviews&trade; in Eukaryotic Gene Expression
JO CRE
YR 2014
FD 2014-10-23
VO 24
IS 4
SP 281
OP 286
K1 breast cancer
K1 DCIS
K1 treatment
AB Nearly 20&#37; of all breast cancer cases are ductal carcinoma <i>in situ</i> (DCIS), with over 60,000 cases diagnosed each year. Many of these cases would never cause clinical symptoms or threaten the life of the woman; however, it is currently impossible to distinguish which lesions will progress to invasive disease from those that will not. DCIS is generally associated with an excellent prognosis regardless of the treatment pathway, but there is variation in treatment aggressiveness that seems to exceed the medical uncertainty associated with DCIS management. Therefore, it would seem that a significant proportion of women with DCIS receive more extensive treatment than is needed. This overtreatment of DCIS is a growing concern among the breast cancer community and has implications for both the patient (via adverse treatment-related effects, as well as out-of-pocket costs) and society (via economic costs and the public health and environmental harm resulting from health care delivery). This article discusses DCIS treatment pathways and their implications for patients and society and calls for further research to examine the factors that are leading to such wide variation in treatment decisions.
PB Begell House
LK https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,76b3452a55cd7eeb,12667f0538d1e135.html